Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000730343 | SCV000858072 | uncertain significance | not provided | 2017-11-08 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578758 | SCV001806061 | uncertain significance | Bardet-Biedl syndrome 13 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578759 | SCV001806062 | uncertain significance | Joubert syndrome 28 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578760 | SCV001806063 | uncertain significance | Meckel syndrome, type 1 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000730343 | SCV005192975 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV004733030 | SCV005365316 | uncertain significance | MKS1-related disorder | 2024-04-30 | no assertion criteria provided | clinical testing | The MKS1 c.1465C>T variant is predicted to result in the amino acid substitution p.Arg489Cys. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |